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Objectives This study aims to address whether D85N, a KCNE1 polymorphism, is a gene variant that causes long QT syn-
drome (LQTS) phenotype.
Background KCNE1 encodes the beta-subunit of cardiac voltage-gated K channels and causes LQTS, which is characterized
by the prolongation of the QT interval and torsades de pointes, a lethal arrhythmia. D85N, a KCNE1 polymor-
phism, is known to be a functional variant associated with drug-induced LQTS.
Methods In order to elucidate the prevalence and clinical significance of this polymorphism, we performed genetic screen-
ing in 317 LQTS probands. For comparison, we examined its presence in 496 healthy control subjects. We also
conducted biophysical assays for the D85N variant in mammalian cells.
Results The allele frequency for D85N carriers was 0.81% in healthy people. In contrast, among LQTS probands, there
were 1 homozygous and 23 heterozygous carriers (allele frequency 3.9%). Seven of 23 heterozygous carriers
had additional mutations in LQTS-related genes, and 3 female subjects had documented factors predisposing to
the symptom. After excluding these probands, the D85N prevalence was significantly higher compared with con-
trol subjects (allele frequency 2.1%, p  0.05). In a heterologous expression study with Chinese hamster ovarian
cells, KCNE1-D85N was found to exert significant loss-of-function effects on both KCNQ1- and KCNH2-encoded
channel currents.
Conclusions The KCNE1-D85N polymorphism was significantly more frequent in our LQTS probands. The functional variant is
a disease-causing gene variant of LQTS phenotype that functions by interacting with KCNH2 and KCNQ1. Since
its allele frequency was 1% among control individuals, KCNE1-D85N may be a clinically important genetic
variant. (J Am Coll Cardiol 2009;54:812–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.005a
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gong QT syndrome (LQTS) is a disorder that is charac-
erized by repolarization abnormalities in the heart, leading
o torsades de pointes (TdP), syncope, and sudden death.
mong the LQTS-related genes identified to date,
CNQ1 and KCNE1 are known to encode the alpha and
eta subunits of voltage-gated K channels, which carry IKs,
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Manuscript received September 8, 2008; revised manuscript received May 21, 2009,
ccepted June 15, 2009.slowly activating component of delayed rectifier K
urrent (1,2). KCNE1 is also known to regulate KCNH2
3), which encodes the Kv11.1 protein, the alpha subunit of
apidly activating delayed rectifier K current (IKr) (4–6).
See page 820
A KCNE1 C-terminal polymorphism, D85N, has been
ound in the normal population and is known to cause a
-to-A transition at codon 253 (c.253GA), which leads
o the amino acid substitution of aspartic acid for aspara-
ines (7). This has been shown to cause an approximately
0% reduction in KCNQ1-encoded currents in a heterolo-
ous expression system using Xenopus oocytes (8), although
iophysical study data are not available for mammalian cells.
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August 25, 2009:812–9 A Functional Common Variant in LQTShe allele frequency of the polymorphism is reported to be
.7% in apparently healthy Asians (7). Paulussen et al. (9)
emonstrated in a European population that the allele
requency of D85N was 5% in acquired LQTS patients who
xperienced TdP as a result of drug administration, but was
% in the control group. Iwasa et al. (10) reported that the
llele frequency was 2% in 100 Japanese cases, but their cohort
ontained both LQTS patients and normal individuals.
In the present study, we examined the incidence rate of
CNE1-D85N polymorphisms in 317 LQTS probands
rom unrelated families and 496 control healthy individuals.
e identified 23 heterozygous and 1 homozygous probands
allele frequency 3.9%), described the demographics of these
ndex patients, and examined the possibility that the D85N
olymorphism is an LQTS-causing genetic variant. We also
onducted detailed functional assays of the variant while it
as coexpressed with the 2 alpha subunits of cardiac delayed
ectifier K channels, KCNQ1 and KCNH2, by using a
eterologous expression system involving Chinese hamster
varian (CHO) cells.
ethods
tudy subjects. Three hundred and seventeen consecutive
QTS probands who showed a prolongation of the QT
nterval were referred to our laboratory for genetic evaluation
nd were enrolled in our analysis. The electrocardiogram
iagnostic criteria of Keating and Sanguinetti (11) included a
orrected QT interval (QTc) of 470 ms in asymptomatic
ndividuals and a QTc of 440 ms for male subjects and of
460 ms for female subjects that had 1 or more of the
ollowing: 1) stress-related syncope; 2) documented TdP; or
) a family history of early sudden cardiac death.
The protocol for genetic analysis was approved by our
nstitutional ethics committee and was performed under its
uidelines. Informed consent was obtained from all individ-
als or their guardians before the analysis. The QT intervals
ere measured from electrocardiographic lead II or an
vailable rhythm strip and were corrected for heart rate
ccording to Bazett’s formula. As for the control cohort, we
creened the frequency of the D85N polymorphism in 496
andomly selected cases, consisting of healthy volunteers
nd mutation-negative family members such as probands’
pouses. Their QTc were 440 ms for male subjects and
460 ms for female subjects.
enotyping. Genomic deoxyribonucleic acid (DNA) was
solated from venous blood by use of the QIAamp DNA
idikit (Qiagen, Hilden, Germany). Genetic screening for
CNE1-D85N was performed by direct polymerase chain
eaction. Other LQTS-related genes, including KCNQ1,
CNH2, SCN5A, KCNE1, KCNE2, and KCNJ2, were
ssayed by denaturing high-performance liquid chromatogra-
hy using a WAVE System Model 3500 (Transgenomic,
maha, Nebraska). Abnormal conformers were amplified byolymerase chain reaction. Sequencing was performed with an sBI PRISM3100 DNA se-
uencer (Applied Biosystems,
ellesley, Massachusetts).
ite-directed mutagenesis. Com-
lementary deoxyribonucleic acid
cDNA) for human KCNQ1
GenBank AF000571) and
CNE1 (GenBank M26685)
ere kindly provided by Dr. J.
arhanin (Institut de Pharmacolo-
ie Moléculaire et Cellulaire, CNRS, Valbonne, France). The
DNAs were subcloned into pIRES2-EGFP (for KCNQ1)
nd pIRES-CD8 (for both wild-type and mutated KCNE1)
ectors. cDNA for human KCNH2 (GenBank AF363636)
as kindly donated by Dr. M. Sanguinetti (University of
tah, Salt Lake City, Utah). The cDNA was subcloned into
pRc-CMV vector. A KCNE1-D85N variant was con-
tructed using a Quick Change II XL Site-Directed Mu-
agenesis Kit, according to the manufacturer’s instructions
Stratagene, La Jolla, California). Nucleotide sequence anal-
sis was performed on each variant construct before the
xpression study to confirm their sequences.
ell transfection. CHO cells were maintained at 37°C in
ulbecco’s modified Eagle medium and Ham’s F12 nutri-
ional mixture (Gibco-BRL, Rockville, Maryland) contain-
ng 10% fetal bovine serum supplemented with 1% penicil-
in and 1% streptomycin. Wild-type KCNQ1, KCNH2,
nd wild-type and/or variant KCNE1 clones were expressed
ransiently in CHO cells using the LipofectAMINE
ethod according to the manufacturer’s instructions (In-
itrogen, Carlsbad, California).
To identify the cells that were positive for KCNH2
xpression, CHO cells were cotransfected with 1 g of
Rc-CMV/KCNH2 vector and 0.5 g of pEGFP-N1/
MV vector. Forty-eight to 72 h after transfection, green
uorescent protein-positive cells and anti-CD8 antibody-
oated bead (Dynabeads CD8, Dynal Biotech, Oslo, Nor-
ay) decorated cells were used for the patch-clamp study.
lectrophysiological assays. Whole-cell configuration of
atch-clamp techniques was employed to record membrane
urrents at 37°C with an EPC-8 patch-clamp amplifier
HEKA, Lambrecht, Germany). Pipette resistance ranged
rom 2.5 to 4 M when filled with the pipette solutions
escribed in the following text. The series resistance was
lectronically compensated for at 70% to 85%. The extra-
ellular solution contained (mmol/l): 140 NaCl, 0.33
aH2PO4, 5.4 KCl, 1.8 CaCl2, 0.5 MgCl2, 5.5 glucose,
nd 5 HEPES, and the pH was adjusted to 7.4 with NaOH.
he internal (pipette) solution contained (mmol/l): 70
otassium aspartate, 70 KOH, 40 KCl, 10 KH2PO4, 1
g2SO4, 3 Na2-ATP, 0.1 Li2-GTP, 5 EGTA, and 5
EPES, and the pH was adjusted to 7.2 with KOH.
KCNQ1/KCNE1-encoded currents were measured by
epolarizing pulses from a holding potential of 90 mV to
est potentials between 70 and 50 mV (with a 10-mV
Abbreviations
and Acronyms
CHO  Chinese hamster
ovarian
LQTS  long QT syndrome
QTc  corrected QT
interval
TdP  torsades de pointestep increment), before being repolarized to 50 mV in
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A Functional Common Variant in LQTS August 25, 2009:812–9rder to monitor tail current amplitude. KCNH2/KCNE1-
ncoded currents were elicited by depolarizing pulses from a
olding potential of 80 mV to test potentials between
60 to 50 mV (with a 10-mV step increment), before
eing repolarized to 60 mV in order to monitor tail
urrent amplitude. Current densities (pA/pF) were calcu-
ated for each cell studied, by normalizing peak tail current
mplitude to cell capacitance (Cm). The Cm was calculated
y fitting a single exponential function to the decay phase of
he transient capacitive current in response to  5 mV
oltage steps (20 ms) from a holding potential of 50 mV.
he liquid junction potential between the test solution and
he pipette solution was measured as approximately 10
V and was corrected. Data were collected and analyzed
sing the Patch master and Igor Pro (WaveMetrics, Lake
swego, Oregon).
ata analyses. The voltage-dependence of current activa-
ion was determined by fitting the normalized tail current
Itail) versus test potential (Vtest) to Boltzmann’s function,
hich is expressed by: Itail  1/(1  exp [(V0.5  Vt)/k]),
here V0.5 is the voltage at which the current is half-
ctivated and k is the slope factor. Time constants for
eactivation (fast and slow) were obtained by fitting a
-exponential function to the time course of the deactivat-
ng tail currents. All data are expressed as mean  standard
rror. Statistical comparisons were made using analysis of
ariance, followed by a t test, and differences were consid-
red significant at a value of p  0.05.
Clinical Characteristics of the LQTS Probands WTable 1 Clinical Characteristics of the LQTS
Patient # Age (F/M) QTc (ms) Syncope TdP
1 36 (F) 540  
2 9 (M) 478  
3 21 (F) 533   K
4 42 (F) 650  
5 51 (F) 490   K
6 73 (F) 493  
7 30 (F) 502   K
8 17 (F) 470  
9 13 (F) 462   K
10 41 (F) 490  
11 73 (F) 608   K
12 75 (F) 494  
13 17 (M) 500  
14 13 (F) 512  
15 57 (M) 472  
16 53 (M) 462  
17 17 (F) 520  
18 22 (F) 472  
19 13 (F) 522   K
20 13 (M) 467  
21 52 (M) 524   K
22 11 (M) 491  
23 51 (M) 493  
24 39 (F) 545  *Novel variant.
LQTS  long QT syndrome; QTc  corrected QT interval; TdP  torsades desults
linical characteristics and genotyping. Of the 496 con-
rol volunteers, 8 (mean QTc 420.5  7.5 ms) had het-
rozygous D85N genotypes (allele frequency 0.81%). In
ontrast, 23 of the 317 LQTS probands had heterozygous
85N genotypes and 1 (Table 1) (Patient #24) had a
omozygous D85N genotype (allele frequency 3.9%). Table
and Figure 1 summarize the demographics of the 24 index
atients. Their mean age was 34.8  4.4 years, and their
ean QTc was 507.9 9.2 ms. Among the D85N-negative
ases, we identified 116 probands that were positive for
ther LQTS-related gene mutations (Fig. 1), and their
ean QTc was significantly longer (540.6  6.1 ms) than
hose of the 24 D85N carriers (p  0.05).
Seven of the 23 heterozygous probands (30%) had other
QTS-related gene variants (KCNQ1 or KCNH2), and 3
emale patients (13%; Patients #1, #6, and #10) had docu-
ented predisposing factors, such as electrolyte distur-
ances, QT prolonging drug intake, or bradycardia (Table
). The allele frequency of the remaining 13 patients
2.1%) was significantly higher than that in the control
ubjects (p  0.05). Six of these 13 patients (46%) had
yncope and/or TdP while 9 of 10 patients (90%) with
ultiple genetic variants or triggering factors were symp-
omatic (Fig. 1).
The mean onset age of the 6 symptomatic heterozygous
85N carriers without compromised factors to affect QT
arried the KCNE1-D85N Variantands Who Carried the KCNE1-D85N Variant
ound Variant Underlying Predisposing Triggers
Drug (bromocriptine), hypokalemia
(a, S706F)* Drug (amphetamine), hypokalemia
(a, E58K) Sinus bradycardia
Drug (disopyramide), sinus bradycardia
(G745fs55X)*
(a, S320L)
Hypomagnesemia
(a, S277L) Sinus bradycardia
(a, R823W)
(a, R948S)* Drug (minor tranquilizer), hypokalemiaho CProb
Comp
CNH2
CNH2
CNH2
CNH2
CNQ1
CNH2
CNH2e pointes.
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August 25, 2009:812–9 A Functional Common Variant in LQTSnterval was 35.5  10.4 years. It was significantly older
han the mean onset age of the other genotyped symptom-
tic LQTS patients (21.0 years in our cohort of 94 geno-
yped LQTS) (Horie M. et al., unpublished data, Septem-
er 2008). Although the clinical features of KCNE1-
85N–positive probands differed with respect to the QTc
nd the onset age from those of other genotyped LQTS
atients, this variant appeared to be a disease-causing gene
ariant in congenital LQTS.
iophysical assays of the genetic variant. KCNE1-D85N
ITH KCNQ1. In order to confirm that the D85N is a
isease-causing variant, we conducted functional assays
sing a heterologous expression system with a mammalian
ell line (CHO cells). In the first line of experiments, we
xamined how KCNE1-D85N affected the reconstituted
CNQ1/KCNE1 currents. Figure 2 depicts representative
urrent traces recorded from cells that coexpressed KCNQ1
nd wild-type (Fig. 2A-a) or D85N (Fig. 2A-b) KCNE1 (1
g each). Peak tail current densities measured after repo-
arization to 50 mV from various test pulses were calcu-
ated in individual cells and are plotted as a function of test
otential in Figure 2B. Solid circles indicate the mean peak
urrent densities from 21 cells that were transfected with
CNQ1 and wild-type KCNE1; open circles indicate the
ean peak current densities from 25 cells that were trans-
ected with KCNQ1 and D85N, and solid triangles indicate
LQTS pro
No other mutation and triggers;  13
Syncope or TdP;  6
  D85N heter D85N homozygous;  1
  
No symptoms;  7
D85N posit
  (QTc=507.9
  (QTc=506  (QTc=545.0
  (QTc=498.5
  (QTc=517.5   (QTc=482.3
Figure 1 Summary of LQTS Probands
LQTS  long QT syndrome; QTc  corrected QT interval; TdP  torsades de pointehe mean peak current densities from 25 cells that were cransfected with KCNQ1 alone. D85N reduced the peak
ail currents of wild-type KCNQ1/KCNE1-encoded cur-
ents by 28% at 0 mV test potential (p 0.05 vs. wild type).
In Figure 2C, peak tail current densities have been
ormalized using the current densities recorded after a test
ulse to 50 mV and are plotted as a function of test
otential. Fitting of data plots to Boltzmann’s equation
ielded V0.5 values of4.36 1.8 mV for the wild type and
.38  1.7 mV for D85N (p  0.05), suggesting that the
CNE1 variant produced a significantly positive shift in
CNQ1-encoded current activation kinetics (Table 2). The
eactivation process of tail currents could be fitted by 2
xponentials, yielding fast and slow time constants. No
ignificant difference with respect to the fast time constants
as evident between the wild-type and D85N genotypes;
owever, slow deactivation was significantly accelerated by
oexpression of D85N (Table 2).
CNE1-D85N WITH KCNH2. In the next line of experiments,
e examined how KCNE1 and its D85N variant influence
CNH2-encoded currents. Figures 3A-a and 3A-b depict
sets of current traces recorded from CHO cells that had
een transfected with KCNH2 plus wild-type or D85N
CNE1 (1 g each). Peak tail current densities at –60 mV
ere calculated in the respective cells and are plotted as a
unction of test potential in Figure 3B. Solid circles and open
;  317
Other mutation or triggers;  10
Syncope or TdP;  9
us;  23
D85N negative;  293
with mutation;  116
(QTc=540.6
No symptoms;  1
4
  (QTc=516.4
  (QTc=515.8   (QTc=522.0bands
ozygo
ive;  2
.3
s.ircles indicate the mean current densities calculated from 23
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A Functional Common Variant in LQTS August 25, 2009:812–9nd 20 cells, respectively, which were transfected with 1 g of
CNH2 and 1 g of wild-type or D85N KCNE1.
D85N reduced the peak tail currents of wild-type
CNH2/KCNE1-encoded currents by 31% to 36% at test
otentials between 0 and50 mV (p 0.005 vs. wild type).
itting of normalized data to Boltzmann’s equation yielded
V0.5 of 18.33  0.8 mV for the wild-type KCNH2/
CNE1 and of 22.07  1.6 mV for KCNH2/KCNE1-
85N (p  0.05), suggesting that the KCNE1 variant
auses a significantly negative shift of KCNH2/KCNE1-
ncoded current activation kinetics (Fig. 3C, Table 2).
eactivation of tail currents could be fitted by 2 exponen-
Figure 2 Functional Expression of KCNQ1 With KCNE1-D85N in
(A) Representative current traces of KCNQ1 coexpression with the wild-type (WT) o
D85N KCNE1 (1 g). (B and C) Functional consequences of KCNQ1 coexpression
Solid circles indicate the mean peak current densities from 21 cells that have bee
the mean peak current densities from 25 cells that have been transfected with KC
25 cells that were transfected with KCNQ1 alone (1 g).ials, yielding fast and slow time constants. The fast and hlow kinetics were not significantly different between the 2
ypes of KCNH2 channel currents (Table 2).
iscussion
he present study demonstrates that the allele frequency of
CNE1-D85N is significantly higher in LQTS patients than
n control subjects after excluding cases with compromised
actors to prolong QT interval (p 0.05). A biophysical assay
f D85N showed that the variant affected both reconstituted
Ks and IKr channel function, leading to a prolongation of the
Tc with D85N working as a disease-causing variant. In a
ese Hamster Ovarian Cells
N KCNE1. (a) KCNQ1 (1 g) plus WT KCNE1 (1 g). (b) KCNQ1 (1 g) plus
he WT or D85N KCNE1 ([B] activation curve; [C] normalized activation curve).
sfected with KCNQ1 and WT KCNE1 (1 g of each), and open circles indicate
nd D85N KCNE1 (1 g of each). Solid triangles show those obtained fromChin
r D85
with t
n tran
NQ1 aeterologous expression system with Xenopus oocytes (8),
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August 25, 2009:812–9 A Functional Common Variant in LQTSCNE1-D85N has been reported to cause an approximately
0% reduction in KCNQ1-encoded currents, although data
or mammalian cells is not available. In our experiments using
HO cells, D85N significantly reduced KCNQ1-encoded
urrents by 28% (p  0.05 vs. wild type), although this effect
as smaller than that in Xenopus oocytes.
Figure 3 Functional Expression of KCNH2 With KCNE1-D85N in
(A) Representative current traces of KCNH2 coexpression with the wild-type (WT) o
D85N KCNE1 (1 g). (B and C) Functional consequences of KCNH2 coexpression
Solid circles indicate data from 23 cells that were transfected with KCNH2 and W
fected with KCNH2 and D85N KCNE1 (1 g of each).
0.5, Slope Factor k, and  Deactivation at 20 mVTable 2 V0.5, Slope Factor k, and  Deactivation at 20 mV
n V0.5
KCNQ1 (WT) 1 g 25 20.86 1.034
KCNQ1 (WT) 1 g/KCNE1 (WT) 1 g 21 4.364 1.834*
KCNQ1 (WT) 1 g/KCNE1 (D85N) 1 g 25 0.382 1.717*
KCNH2 (WT) 1 g/KCNE1 (WT) 1 g 23 18.326 0.775
KCNH2 (WT) 1 g/KCNE1 (D85N) 1 g 20 22.069 1.560§
p  0.0001 versus KCNQ1 (wild type [WT]) 1 g; †p  0.0001 versus KCNQ1 (WT) 1 g; ‡p  0When KCNH2 was coexpressed with the wild-type or
85N variant of KCNE1, D85N significantly reduced
ild-type KCNH2/KCNE1-encoded currents by 31% to
6% (p  0.005 vs. wild type). Regarding the interaction
etween KCNE1 and KCNH2, McDonald et al. (3) dem-
nstrated that KCNE1 forms a stable complex with KCNH2 and
ese Hamster Ovarian Cells
N KCNE1. (a) KCNH2 (1 g) plus WT KCNE1 (1 g). (b) KCNH2 (1 g) plus
he WT or D85N of KCNE1 ([B] activation curve; [C] normalized activation curve).
E1 (1 g of each). Open circles indicate data from 20 cells that were trans-
k fast slow
8.223 0.421 0.070 0.005 0.136 0.019
12.724 0.407* 0.145 0.013* 0.586 0.070†
12.566 0.429* 0.141 0.013* 0.409 0.050*‡
7.373 0.289 0.183 0.016 1.077 0.102
7.037 0.389 0.193 0.013 1.258 0.090
sus KCNQ1 (WT) 1 g/KCNE1 (WT) 1 g; §p  0.05 versus KCNH2 (WT) 1 g/KCNE1 (WT) 1 g.Chin
r D85
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A Functional Common Variant in LQTS August 25, 2009:812–9p-regulates IKr-like currents by 50% in CHO cells. Bianchi
t al. (12) also showed interactions between the KCNE1-
76N mutation and both KCNQ1 and KCNH2 in HEK
ells. In atrial tumor myocytes that expressed IKr alone,
ang et al. (13) demonstrated that antisense oligonucleo-
ides against minK cDNA (KCNE1) significantly reduced
he IKr by 62%. More recently, Ohno et al. (14) identified
missense KCNE1 mutation, A8V, in a sporadic case of
QTS and reported that the mutation significantly reduced
he magnitude of KCNH2- but not KCNQ1-encoded
urrents.
Collectively, it is of clinical importance that the KCNE1-
85N variant modifies not only KCNQ1- but also
CNH2-coded channel currents. Furthermore, its inhibi-
ory action on KCNH2 was even stronger than that on
CNQ1. The KCNE1-D85N polymorphism may there-
ore cause phenotypes similar to those observed in type 2
QTS such as bradycardia (15,16). The deactivation pro-
ess of IKr plays a significant role in maintaining the appro-
riate rate of pacemakers (17) and, therefore, a decreased IKr
ill lead to sinus bradycardia. In the present study, 3 D85N
arriers (13%) had sinus bradycardia (Table 1).
The mean onset age of 6 symptomatic heterozygous
85N carriers (Table 1) was 35.5 years, and this was
ignificantly older than the mean age of other genotyped
ymptomatic LQTS patients. Shimizu et al. (18) reported
hat in 95 Japanese LQT1 patients with transmembrane
omain mutations or C-terminal domain mutations, the
ean ages of first event were 11 8 years and 13 9 years.
agaoka et al. (19) also demonstrated that in 118 Japanese
QT2 patients with pore mutations or nonpore mutations,
he mean ages of first event were 16  10 years and 20 
3 years. In addition, the mean QTc of 13 D85N carriers
as prolonged (498.5  13.6 ms) but significantly shorter
han that in 116 probands with other LQTS-related gene
utations (541 ms) (Fig. 1). These different phenotypes
ppear to reflect the fact that D85N causes a milder channel
ysfunction than other LQTS mutations, and reveals a
forme fruste” phenotype (20).
The allele frequency of the KCNE1-D85N polymor-
hism was 0.81% among apparently healthy control indi-
iduals. We found only 1 report concerning D85N fre-
uency (0.7%) (7) in control subjects, which showed
quivalent results to our study. Based on 2008 healthy
rench individuals, Gouas et al. (21) demonstrated that the
llele frequency of D85N was significantly higher in the 200
ubjects with the longest QTc than in those with the
hortest QTc (3.1% vs. 0.75%), suggesting that this single
ucleotide polymorphism may influence the QTc length in
ealthy individuals.
LQTS can remain latent or subclinical because of “repo-
arization reserve” (22), and can become unmasked upon the
ntake of QT-prolonging drugs. Heterozygous D85N car-
iers in the control group may be at a potentially higher risk
f long QT-related arrhythmias. Assuming that genetic
urveys are feasible before drug therapy, D85N carriers maye recommended to avoid the secondary factors that pre-
ispose them to further QT prolongation such as QT
rolonging drugs (23) and electrolyte disturbances (23–25).
t is also clinically useful to search for other variants of long
T-related genes (8,26,27).
tudy limitations. In the present study, we screened the
utations that are responsible for LQT1, 2, 3, 5, 6, and 7.
herefore, the comorbidity of other types of LQTS was not
ompletely excluded, although their frequency was quite
ow. In general, single nucleotide polymorphisms are thought to
e nonpathological although some may modify the clinical
eatures of a disease. For example, the KCNH2-K897T
olymorphism is a typical genetic modifier that aggravates
QTS phenotypes directly by reducing channel function in
ssociation with the KCNH2 mutation A1116V (28). Such
role for KCNE1-D85N was not addressed in this study
nd warrants further study.
onclusions
CNE1-D85N was a highly frequent variant in our LQTS
robands and was found to cause loss-of-function effects on
oth IKr and IKs and work as a disease-causing variant. Since
ts allele frequency was 0.81% among control healthy
ndividuals, KCNE1-D85N may be a clinically important
enetic variant.
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